Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFRm Metastatic Non-Small Cell Lung Cancer”

33 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 33 results

Early research (Phase 1)Looking for participantsNCT06147037
What this trial is testing

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Who this might be right for
Advanced Solid TumorMetastatic Colorectal CarcinomaHead and Neck Squamous Cell Carcinoma+4 more
AstraZeneca 70
Not applicableApproved For MarketingNCT06279728
What this trial is testing

Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

Who this might be right for
EGFRm Advanced Non-Small Cell Lung CancerEGFRm Metastatic Non-Small Cell Lung Cancer
Daiichi Sankyo
Testing effectiveness (Phase 2)Active Not RecruitingNCT05801029
What this trial is testing

Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Testing effectiveness (Phase 2)Ended earlyNCT02630186
What this trial is testing

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 3
Testing effectiveness (Phase 2)UnknownNCT06195189
What this trial is testing

Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II

Who this might be right for
Non Small Cell Lung Cancer
Sichuan University 40
Large-scale testing (Phase 3)Active Not RecruitingNCT04143607
What this trial is testing

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 337
Not applicableUnknownNCT02803619
What this trial is testing

A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis

Who this might be right for
Non-small Cell Lung CancerLeptomeningeal Metastasis
Peking Union Medical College Hospital 60
Not applicableStudy completedNCT06039683
What this trial is testing

A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 54
Testing effectiveness (Phase 2)Active Not RecruitingNCT03778229
What this trial is testing

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Who this might be right for
Carcinoma
AstraZeneca 367
Large-scale testing (Phase 3)Active Not RecruitingNCT04765059
What this trial is testing

Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 98
Not applicableLooking for participantsNCT06422546
What this trial is testing

A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Beijing Cancer Prevention & Treatment Society 950
Testing effectiveness (Phase 2)Study completedNCT04770688
What this trial is testing

Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib

Who this might be right for
Non-Small Cell Lung Cancer With EGFR MutationLocally Advanced Solid TumorMetastatic Cancer+1 more
Shanghai Chest Hospital 25
Early research (Phase 1)Not Yet RecruitingNCT06218940
What this trial is testing

HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC

Who this might be right for
NSCLC Stage IV
Newsoara Biopharma Co., Ltd. 40
Large-scale testing (Phase 3)Study completedNCT02296125
What this trial is testing

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AstraZeneca 674
Testing effectiveness (Phase 2)Looking for participantsNCT06574347
What this trial is testing

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 120
Large-scale testing (Phase 3)Active Not RecruitingNCT05338970
What this trial is testing

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Who this might be right for
Nonsquamous Non-small Cell Lung CancerEGFR L858REGFR Exon 19 Deletion
Daiichi Sankyo 586
Not applicableLooking for participantsNCT06643000
What this trial is testing

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Who this might be right for
Non-small Cell Lung CancerLeptomeningeal MetastasisEGFR Gene Mutation
Henan Cancer Hospital 60
Large-scale testing (Phase 3)Active Not RecruitingNCT05009836
What this trial is testing

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Hutchison Medipharma Limited 320
Not applicableUnknownNCT04778800
What this trial is testing

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

Who this might be right for
NSCLCBrain MetastasesLeptomeningeal Metastasis
Henan Cancer Hospital 60
Testing effectiveness (Phase 2)Looking for participantsNCT07058519
What this trial is testing

Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

Who this might be right for
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
Shanghai Chest Hospital 250
Load More Results